Published in J Intern Med on September 01, 2004
Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT) | NCT03683394
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med (2016) 5.55
Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med (2008) 5.34
Mild cognitive impairment: ten years later. Arch Neurol (2009) 5.02
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology (2010) 4.06
Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology (2010) 3.83
Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology (2006) 3.72
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology (2009) 3.65
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA (2015) 3.48
Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol (2009) 3.35
Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology (2006) 3.22
Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ (2006) 2.79
MCI is associated with deficits in everyday functioning. Alzheimer Dis Assoc Disord (2006) 2.71
Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol (2009) 2.66
Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med (2011) 2.61
Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA (2009) 2.59
Leisure activities and the risk of amnestic mild cognitive impairment in the elderly. Neurology (2006) 2.51
Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry (2006) 2.48
Regional pattern of white matter microstructural changes in normal aging, MCI, and AD. Neurology (2009) 2.47
Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry (2008) 2.39
Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp (2009) 2.24
Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement (2012) 2.13
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol (2010) 2.12
Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment. J Am Geriatr Soc (2013) 2.11
Gait phenotype from mild cognitive impairment to moderate dementia: results from the GOOD initiative. Eur J Neurol (2015) 2.11
Support vector machine-based classification of Alzheimer's disease from whole-brain anatomical MRI. Neuroradiology (2008) 2.09
Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement (2010) 2.07
Physical exercise, aging, and mild cognitive impairment: a population-based study. Arch Neurol (2010) 2.02
Gait dysfunction in mild cognitive impairment syndromes. J Am Geriatr Soc (2008) 2.00
Mild cognitive impairment in prediagnosed Huntington disease. Neurology (2010) 1.96
Performance-based measures of everyday function in mild cognitive impairment. Am J Psychiatry (2010) 1.96
Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. Neuroimage (2009) 1.95
Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry (2008) 1.93
Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med (2009) 1.90
Characterization of activities of daily living in individuals with mild cognitive impairment. Am J Geriatr Psychiatry (2008) 1.86
Patterns of atrophy differ among specific subtypes of mild cognitive impairment. Arch Neurol (2007) 1.84
Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol (2011) 1.84
White matter hyperintensity penumbra. Stroke (2011) 1.78
Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. Neuroimage (2008) 1.74
Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med (2007) 1.68
Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol (2013) 1.68
Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol (2009) 1.68
Memory complaints are related to Alzheimer disease pathology in older persons. Neurology (2006) 1.67
The relationship between blood pressure and cognitive function. Nat Rev Cardiol (2010) 1.66
Mild cognitive impairment: a concept in evolution. J Intern Med (2014) 1.65
Short-term practice effects in amnestic mild cognitive impairment: implications for diagnosis and treatment. Int Psychogeriatr (2008) 1.64
Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol (2011) 1.63
Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother (2008) 1.63
Differential FDDNP PET patterns in nondemented middle-aged and older adults. Am J Geriatr Psychiatry (2009) 1.62
Differential memory test sensitivity for diagnosing amnestic mild cognitive impairment and predicting conversion to Alzheimer's disease. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn (2009) 1.61
Health-related resource use and costs in elderly adults with and without mild cognitive impairment. J Am Geriatr Soc (2013) 1.59
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging (2011) 1.57
Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol (2014) 1.56
Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. Neuroimage (2009) 1.55
Mild cognitive impairment: an epidemiological perspective. Dialogues Clin Neurosci (2004) 1.53
Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurol (2014) 1.51
Verbal fluency performance in amnestic MCI and older adults with cognitive complaints. Arch Clin Neuropsychol (2008) 1.51
Functional impairment in elderly patients with mild cognitive impairment and mild Alzheimer disease. Arch Gen Psychiatry (2011) 1.50
Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected]. Medicine (Baltimore) (2014) 1.50
Patterns of mild cognitive impairment after treatment of depression in the elderly. Am J Geriatr Psychiatry (2009) 1.48
Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry (2005) 1.47
Satisfaction With a Family-Focused Intervention for Mild Cognitive Impairment Dyads. J Nurs Scholarsh (2016) 1.47
Spectrum of cognition short of dementia: Framingham Heart Study and Mayo Clinic Study of Aging. Neurology (2015) 1.46
Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology (2008) 1.45
Prevalence of mild cognitive impairment by multiple classifications: The Monongahela-Youghiogheny Healthy Aging Team (MYHAT) project. Am J Geriatr Psychiatry (2010) 1.45
Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry (2009) 1.44
Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia. J Neurol Neurosurg Psychiatry (2009) 1.43
Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch Arztebl Int (2011) 1.43
Exercise-induced cognitive plasticity, implications for mild cognitive impairment and Alzheimer's disease. Front Neurol (2011) 1.41
Instrumental activities of daily living performance and role satisfaction in people with and without mild cognitive impairment: a pilot project. Am J Occup Ther (2015) 1.40
Medical decision-making capacity in cognitively impaired Parkinson's disease patients without dementia. Mov Disord (2008) 1.40
Computer-based cognitive training for mild cognitive impairment: results from a pilot randomized, controlled trial. Alzheimer Dis Assoc Disord (2009) 1.39
The use of advanced tracking technologies for the analysis of mobility in Alzheimer's disease and related cognitive diseases. BMC Geriatr (2008) 1.39
Application and Revision of Montreal Cognitive Assessment in China's Military Retirees with Mild Cognitive Impairment. PLoS One (2016) 1.39
The association between SBP and mortality risk differs with level of cognitive function in very old individuals. J Hypertens (2016) 1.39
Brain aging, Alzheimer's disease, and mitochondria. Biochim Biophys Acta (2011) 1.36
Decisional capacity for research participation in individuals with mild cognitive impairment. J Am Geriatr Soc (2008) 1.35
Dementia risk prediction in the population: are screening models accurate? Nat Rev Neurol (2010) 1.35
Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A (2006) 1.34
Clock drawing test ratings by dementia specialists: interrater reliability and diagnostic accuracy. J Neuropsychiatry Clin Neurosci (2010) 1.33
Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology (2012) 1.33
Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology (2012) 1.31
Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther (2013) 1.30
Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J Alzheimers Dis (2014) 1.30
In vivo analysis of hippocampal subfield atrophy in mild cognitive impairment via semi-automatic segmentation of T2-weighted MRI. J Alzheimers Dis (2012) 1.30
Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch Neurol (2012) 1.29
Coevolution of white matter hyperintensities and cognition in the elderly. Neurology (2012) 1.28
Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimers Dement (2012) 1.28
FLAIR and diffusion MRI signals are independent predictors of white matter hyperintensities. AJNR Am J Neuroradiol (2012) 1.27
Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment. Neuropsychologia (2007) 1.26
Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 1. Alzheimers Dement (2011) 1.26
Mild cognitive impairment and objective instrumental everyday functioning: the everyday cognition battery memory test. J Am Geriatr Soc (2008) 1.26
Cognitive correlates of HVOT performance differ between individuals with mild cognitive impairment and normal controls. Arch Clin Neuropsychol (2006) 1.26
Medical decision-making capacity in mild cognitive impairment: a 3-year longitudinal study. Neurology (2008) 1.25
Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology (1998) 26.77
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology (1993) 16.92
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Dynamic strength of molecular adhesion bonds. Biophys J (1997) 14.93
Energy landscapes of receptor-ligand bonds explored with dynamic force spectroscopy. Nature (1999) 10.45
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology (1997) 8.50
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry (2007) 6.72
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature (1996) 5.50
Sensitive force technique to probe molecular adhesion and structural linkages at biological interfaces. Biophys J (1995) 5.45
SOR: project methodology. Br J Cancer (2001) 5.24
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron (1996) 5.14
Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain (2009) 5.03
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology (2005) 5.02
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology (2000) 4.89
MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology (1992) 4.87
Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci (1998) 4.76
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology (2002) 4.50
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet (1999) 4.17
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Amino acid sequence of the human fibronectin receptor. J Cell Biol (1987) 4.08
Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology (1998) 3.90
Strength of a weak bond connecting flexible polymer chains. Biophys J (1999) 3.88
Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature (1991) 3.86
Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology (2000) 3.84
Nucleotide sequence of the papA gene encoding the Pap pilus subunit of human uropathogenic Escherichia coli. J Bacteriol (1984) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Prion dementia without characteristic pathology. Lancet (1990) 3.66
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology (2006) 3.60
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology (2010) 3.58
Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med (1998) 3.58
The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol (1991) 3.45
Healthy life expectancy: evaluation of global indicator of change in population health. BMJ (1991) 3.45
Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology (2004) 3.41
Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology (2000) 3.39
Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol (2000) 3.37
Separation and characterization of two distinct hemagglutinins contained in purified leukocytosis-promoting factor from Bordetella pertussis. Biochim Biophys Acta (1976) 3.30
MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology (2007) 3.24
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell (1997) 3.17
Biological activities of crystalline pertussigen from Bordetella pertussis. Infect Immun (1981) 3.16
Verifying the stroke-free phenotype by structured telephone interview. Stroke (2000) 3.15
Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg (1969) 3.12
Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology (1989) 3.12
Cloning and sequencing of a Moraxella bovis pilin gene. J Bacteriol (1985) 3.10
The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology (2012) 3.01
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Stroke risk profile, brain volume, and cognitive function: the Framingham Offspring Study. Neurology (2004) 2.97
Predicting changes in physical performance in a high-functioning elderly cohort: MacArthur studies of successful aging. J Gerontol (1994) 2.95
Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis. Infect Immun (1981) 2.94
Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology (2007) 2.93
Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology (2011) 2.91
Longitudinal volumetric MRI change and rate of cognitive decline. Neurology (2005) 2.90
Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med (1983) 2.88
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology (2003) 2.88
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology (1998) 2.83
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation (1999) 2.81
Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology (1999) 2.81
Incident lacunes influence cognitive decline: the LADIS study. Neurology (2011) 2.81
White matter lesions impair frontal lobe function regardless of their location. Neurology (2004) 2.77
High, usual and impaired functioning in community-dwelling older men and women: findings from the MacArthur Foundation Research Network on Successful Aging. J Clin Epidemiol (1993) 2.77
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Utilization of photon orbital angular momentum in the low-frequency radio domain. Phys Rev Lett (2007) 2.72
Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology (2007) 2.72
MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology (2008) 2.69
Social relationships, social support, and patterns of cognitive aging in healthy, high-functioning older adults: MacArthur studies of successful aging. Health Psychol (2001) 2.69
Amantadine and pneumonia. Lancet (1999) 2.69
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology (2012) 2.68
Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology (2002) 2.68
Aphasia rehabilitation resulting from melodic intonation therapy. Cortex (1974) 2.65
Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol (1991) 2.63
Impaired insulin secretion and beta-cell loss in tissue-specific knockout mice with mitochondrial diabetes. Nat Genet (2000) 2.62